Clinical Trials Directory

Trials / Completed

CompletedNCT00813384

A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors

A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 208 in Adult Subjects With Advanced Solid Tumors

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
54 (actual)
Sponsor
Amgen · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

First in human, open-label, sequential dose escalation and expansion study of AMG 208 in subjects with advanced solid tumors.

Conditions

Interventions

TypeNameDescription
DRUGAMG 208AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.

Timeline

Start date
2008-12-01
Primary completion
2013-02-01
Completion
2014-12-01
First posted
2008-12-23
Last updated
2014-12-16

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00813384. Inclusion in this directory is not an endorsement.